HL-400 for Safety Evaluation
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests HL-400, a new treatment that blocks a specific protein (NLRP3) to determine its safety and tolerance in healthy individuals. Participants will take either HL-400 or a placebo (a harmless pill with no active drug) in varying doses to observe the body's response. The trial targets non-smoking individuals who are generally healthy, have not experienced significant health issues, and fall within a specific weight and body mass index (BMI) range. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.
Do I have to stop taking my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. However, since the study is for healthy subjects, it might imply that participants should not be on any regular medications. Please consult with the study team for clarification.
Is there any evidence suggesting that HL-400 is likely to be safe for humans?
A previous study tested HL-400, a type of drug known as a NLRP3 inhibitor, to assess its safety. As a Phase 1 trial, HL-400 is in the early stages of human testing. The primary focus at this stage is identifying any side effects and evaluating how well participants tolerate the drug.
Specific data from past tests on HL-400's safety is not yet available. However, Phase 1 trials typically proceed with caution, starting with low doses and closely monitoring for any issues. This careful approach ensures the drug's safety before broader testing. Testing in healthy individuals, rather than patients, suggests a low risk of severe side effects at this stage.
The goal is to determine HL-400's safety and behavior in the body. While no clear evidence of harm has emerged, the full safety profile is still under development as testing continues.12345Why do researchers think this study treatment might be promising?
Researchers are excited about HL-400 because it offers a novel approach to treatment with its unique delivery method and dosing schedule. Unlike many current treatments that often require more complex administration, HL-400 is administered orally, making it more convenient for patients. Additionally, the treatment involves both single and multiple ascending doses, potentially allowing for tailored dosing strategies that could enhance effectiveness and minimize side effects. This streamlined and flexible approach could offer significant advantages over existing options.
What evidence suggests that HL-400 might be an effective treatment as an NLRP3 inhibitor?
Research shows that HL-400 is a new drug designed to block a protein called NLRP3, which contributes to inflammation. Early tests in labs and animals have demonstrated that targeting NLRP3 can effectively reduce inflammation. Although human studies on HL-400 are limited, the underlying science is promising. Similar drugs targeting NLRP3 have yielded positive results in reducing inflammation in other research. This positions HL-400 as a potential option for treating inflammation-related conditions. Participants in this trial will receive either HL-400 or a placebo to assess its safety and effectiveness.16789
Are You a Good Fit for This Trial?
This trial is for healthy individuals who can participate in a study to test the safety of a new Parkinson's disease drug called HL-400. Specific eligibility criteria are not provided, but typically participants should have no significant health issues that could interfere with the trial.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Single Ascending Dose (SAD)
Participants receive a single oral dose of HL-400 with dose escalation to evaluate safety, tolerability, and pharmacokinetics
Multiple Ascending Dose (MAD)
Participants receive multiple oral doses of HL-400 once daily for 14 days to evaluate safety, tolerability, and pharmacokinetics
Cerebrospinal Fluid (CSF) Exposure
Participants receive multiple oral doses of HL-400 to evaluate pharmacokinetics in the CSF
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- HL-400
Trial Overview
The study tests HL-400, an oral medication intended for Parkinson's disease, against a placebo. It's designed to see how safe it is and how the body reacts to different doses over time. Participants will be randomly assigned to either receive HL-400 or a placebo without knowing which one they're getting.
How Is the Trial Designed?
2
Treatment groups
Active Control
Placebo Group
Part 1:Experimental: Single oral dose of HL-400, Single ascending doses, sequential assignment group design; Part 2: Experimental: Multiple oral doses of HL-400, Multiple ascending doses, once a day (QD) for 14 days, sequential assignment group design; Part 3: Experimental: Multiple oral doses of HL-400, QD for 5 days.
Part 1: Placebo comparator: Single oral dose of placebo, single doses, matching placebo; Part 2: Placebo comparator: Multiple oral doses of placebo, multiple ascending doses, QD for 14 days, matching placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Highlightll Pharmaceutical (USA) LLC
Lead Sponsor
Citations
HL-400 for Safety Evaluation
This is a randomized, double-blind, placebo-controlled, dose-escalation study in healthy subjects to evaluate the safety, tolerability, pharmacokinetics of ...
2.
trial.medpath.com
trial.medpath.com/clinical-trial/24230f18491412a2/nct06997484-hl-400-safety-tolerability-pharmacokinetics-healthy-subjectsFirst-in-Human Single and Multiple Dose of HL-400 | MedPath
This is a randomized, double-blind, placebo-controlled, dose-escalation study in healthy subjects to evaluate the safety, tolerability, pharmacokinetics of HL- ...
Preclinical Evaluation of Safety, Pharmacokinetics, Efficacy ...
These results show that HL-003 is a radioprotective agent with a favorable safety profile, high efficacy, oral administration, and a long half- ...
NCT05008224 | Study of Safety and Efficacy ...
The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) monotherapy, followed by chemotherapy, followed by pembrolizumab ...
217865Orig1s000 INTEGRATED REVIEW - accessdata.fda.gov
... data from the phase 2 study (Study 43) and clinical safety and efficacy data from across the givinostat development program in other.
Safety: Data Sheet | PDF | Firefighting | Polyvinyl Chloride
This document provides a safety data sheet for VORALUX* HL 400 Polyol. It lists the product name and manufacturer identification.
Summary of Safety and Effectiveness Data (SSED)
Stress Relief of. Junctions in. Implantable Leads. To evaluate the resistance to stress of the junctions of the implantable leads of the Neuro Zti Implant.
Guided simulation for dynamic probabilistic risk ...
Guidelines on modeling commoncause failures in probabilistic risk assessment. Safety Programs Division, Office for Analysis and Evaluation of Operational Data, ...
9.
download.basf.com
download.basf.com/p1/000000000030784920_SDS_CPA_00/en_UN/Ilevo_HL_Seed_Treatment_30784920_SDS_CPA_00_en_1-0.pdfIlevo HL Seed Treatment
H400. Very toxic to aquatic life. H301. Toxic if swallowed. H314. Causes severe ... This safety data sheet is neither a. Certificate of Analysis (CoA) nor ...
Other People Viewed
By Subject
By Trial
Related Searches
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.